

## Vedolizumab

Reduce direct handling to a minimum and wear appropriate protective clothing		
CAUTION: High Administration Risk Rating		
<b>Form &amp; Storage</b>	Powder for concentrate for solution for infusion <table border="1" style="float: right; margin-left: 10px;"> <tr> <td style="background-color: #3f51b5; color: white; padding: 2px;">Store in a refrigerator (2°C - 8°C) in the original package to protect from light.</td> </tr> </table>	Store in a refrigerator (2°C - 8°C) in the original package to protect from light.
Store in a refrigerator (2°C - 8°C) in the original package to protect from light.		
<b>Reconstitution</b>	<ul style="list-style-type: none"> <li>• Allow vial to reach room temperature.</li> <li>• Add 4.8mL water for injections, using a syringe with a 21-25 gauge needle, directing the liquid down the wall of the vial to avoid excessive foaming.</li> <li>• Gently swirl the vial for at least 15 seconds. Do not shake vigorously or invert.</li> <li>• Leave for 20 minutes to allow foam to settle; the vial can be gently swirled occasionally during this time.</li> <li>• If not fully dissolved, leave for another 10 minutes. The solution should be clear or opalescent and colourless to light yellow.</li> </ul>	
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9%	
<b>Administration</b>	<p><b><u>IV Infusion</u></b></p> <p>Invert the vial gently three times before withdrawing 5mL of the reconstituted solution with a 21-25 gauge needle. Add to a 250mL infusion bag of sodium chloride 0.9%. Gently mix the contents of the bag. Administer by IV infusion over 30 minutes.</p> <p>See <b>PPG-CUH-CUH-243</b> <u>Policy Procedure and Guidelines for Management of Patients Attending CUH Infusion Unit for Intravenous Therapy CUH</u> for more information</p>	
<b>Documentation Requirements</b>	Document batch numbers and expiry dates of vials in medical notes.	
<b>Adverse Drug Reactions</b>	Medicinal products for the treatment of hypersensitivity reactions, e.g. adrenaline, oxygen, antihistamines and corticosteroids should be available for immediate use in the event of an allergic reaction during administration of all infusions.	
<b>Disposal</b>	Dispose of infusion bag and administration set in purple-lidded bin.	

**Information provided relates to Entyvio® manufactured by Takeda.**

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*